Keyword: Werner Wenning

The confidence vote marks a big win for Werner Baumann as his exec team works to pull the German firm out of the Roundup litigation mire.

A pharma outsider is taking over as Bayer's chairman as it navigates troubles ranging from Roundup suits to challenges facing its new cancer drugs.

Two C-level execs, including one who's under blame for an FDA warning letter, will leave Bayer first thing next year.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.